Lu Z, Du W, Jiao X, Wang Y, et al. Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma". J Clin Oncol 2025 Sep 11:JCO2501535. doi: 10.1200/JCO-25-01535.
PMID: 40934453